532321 Stock Overview
Engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Zydus Lifesciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹972.60 |
| 52 Week High | ₹1,323.90 |
| 52 Week Low | ₹602.10 |
| Beta | 0.42 |
| 11 Month Change | -7.74% |
| 3 Month Change | -25.27% |
| 1 Year Change | 58.73% |
| 33 Year Change | 97.64% |
| 5 Year Change | 315.29% |
| Change since IPO | 15,018.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| 532321 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.9% | 3.0% | 1.6% |
| 1Y | 58.7% | 54.1% | 36.9% |
Return vs Industry: 532321 exceeded the Indian Pharmaceuticals industry which returned 54.1% over the past year.
Return vs Market: 532321 exceeded the Indian Market which returned 36.9% over the past year.
Price Volatility
| 532321 volatility | |
|---|---|
| 532321 Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 532321 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 532321's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 26,921 | Sharvil Patel | zyduslife.com |
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases.
Zydus Lifesciences Limited Fundamentals Summary
| 532321 fundamental statistics | |
|---|---|
| Market cap | ₹979.32b |
| Earnings (TTM) | ₹41.69b |
| Revenue (TTM) | ₹206.15b |
23.5x
P/E Ratio4.8x
P/S RatioIs 532321 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532321 income statement (TTM) | |
|---|---|
| Revenue | ₹206.15b |
| Cost of Revenue | ₹63.05b |
| Gross Profit | ₹143.10b |
| Other Expenses | ₹101.41b |
| Earnings | ₹41.69b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 12, 2024
| Earnings per share (EPS) | 41.43 |
| Gross Margin | 69.41% |
| Net Profit Margin | 20.22% |
| Debt/Equity Ratio | 3.7% |
How did 532321 perform over the long term?
See historical performance and comparison